Insmed (NASDAQ:INSM) reported mixed numbers in its Q4 and 2012 results. For the quarter, the clinical-stage pharmaceutical company didn't report any revenue. In Q4 2011, by contrast, the top line was $1.4 million. Its attributable net loss deepened in this most recent quarter, to $15.5 million ($0.49 per diluted share) from Q4 2011's red figure of $8.2 million ($0.33).
The company also reported no revenue for fiscal 2012. The previous year's figure was $4.4 million. The attributable net loss for 2012, however, narrowed over that time span, to $41.4 million ($1.56 per diluted share) from the prior year's $68.8 million ($2.95).
Insmed's balance sheet has improved over the past 12 months. As of the end of 2012, it had cash and cash equivalents of nearly $93 million, compared with $78.4 million on the last day of 2011.
Fool contributor Eric Volkman and The Motley Fool have no position in Insmed. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.